Back to News
Market Impact: 0.3
Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003
Source: marketbeat.com
Healthcare & BiotechCorporate Guidance & Outlook
Cybin outlined its late-stage depression-program strategy at H.C. Wainwright's Global Investment Conference and expects a Phase 3 data readout for HLP003 in Q4. The upcoming clinical-data catalyst is potentially material for the company, though the article provides no efficacy, safety, or financial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
HELP0.35
More News
- Perpetual underdog AMD nips at Nvidia's heels as it joins the $1T club
- GRAIL Stock Bounces Back Above $100: Can Galleri Sail Through Its FDA Panel Review?
- Ra Capital Management sells $21.8m in Sionna Therapeutics shares
- Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
- Why is Labcorp stock sliding today?
- Why is Quest Diagnostics stock sliding today?